---
provider: asta
model: Asta Scientific Corpus Retrieval
cached: false
start_time: '2026-05-26T23:12:24.842862'
end_time: '2026-05-26T23:12:30.269417'
duration_seconds: 5.43
template_file: templates/hypothesis_deep_research.md
template_variables:
  disease_name: Ovarian High-Grade Serous Carcinoma
  category: ''
  hypothesis_group_id: restored_hrr_reversion_resistance_model
  hypothesis_label: Restored HRR via BRCA Reversion Resistance Model
  hypothesis_status: CANONICAL
  hypothesis_yaml: "hypothesis_group_id: restored_hrr_reversion_resistance_model\n\
    hypothesis_label: Restored HRR via BRCA Reversion Resistance Model\nstatus: CANONICAL\n\
    description: Resistant HGSOC subclones acquire BRCA1, BRCA2, or PALB2 reversion\
    \ mutations that restore\n  HRR function and abolish the synthetic-lethal relationship.\
    \ Reversion alleles are detectable in ctDNA\n  at progression and are the principal\
    \ documented mechanism of clinical PARP-inhibitor resistance.\nevidence:\n- reference:\
    \ PMID:36243543\n  supports: SUPPORT\n  evidence_source: HUMAN_CLINICAL\n  snippet:\
    \ No baseline BRCA reversion mutations were observed in 100 BRCA+ patients. NGS\
    \ identified somatic\n    BRCA reversion mutations in 39% (39/100) of patients\
    \ after progression.\n  explanation: TRITON2 establishes acquired BRCA reversion\
    \ mutations in ~39% of progression specimens\n    as the principal acquired-resistance\
    \ event."
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    query_char_limit: 500
    paper_limit: 50
    snippet_limit: 20
    snippet_paper_limit: 50
    restrict_snippets_to_papers: false
    paper_fields: title,abstract,authors,year,url,venue,journal,tldr,publicationDate,citationCount,influentialCitationCount,externalIds
    publication_date_range: ''
    venues: ''
    inserted_before: ''
citation_count: 18
---

## Question

# Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Ovarian High-Grade Serous Carcinoma
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** restored_hrr_reversion_resistance_model
- **Hypothesis Label:** Restored HRR via BRCA Reversion Resistance Model
- **Status in KB:** CANONICAL

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: restored_hrr_reversion_resistance_model
hypothesis_label: Restored HRR via BRCA Reversion Resistance Model
status: CANONICAL
description: Resistant HGSOC subclones acquire BRCA1, BRCA2, or PALB2 reversion mutations that restore
  HRR function and abolish the synthetic-lethal relationship. Reversion alleles are detectable in ctDNA
  at progression and are the principal documented mechanism of clinical PARP-inhibitor resistance.
evidence:
- reference: PMID:36243543
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: No baseline BRCA reversion mutations were observed in 100 BRCA+ patients. NGS identified somatic
    BRCA reversion mutations in 39% (39/100) of patients after progression.
  explanation: TRITON2 establishes acquired BRCA reversion mutations in ~39% of progression specimens
    as the principal acquired-resistance event.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.


## Output

# Asta Literature Retrieval: Mechanistic Hypothesis Search You are evaluating a specific disease mechanism hypothesis for the Disorder Mechanisms...

This report is retrieval-only and is generated directly from Asta results.

- Papers retrieved: 18
- Snippets retrieved: 20

## Relevant Papers

### [1] Gathering Evidence of Mechanisms
- Authors: Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, B. Clarke, P. Illari et al.
- Year: 2018
- Venue: Unknown venue
- URL: https://www.semanticscholar.org/paper/06480fd932fc88915a4efb4c894a5ae4ed98452d
- DOI: 10.1007/978-3-319-94610-8_5
- Citations: 1
- Summary: Key issues include increased precision concerning the nature of the hypothesis being examined, attention to differences between the study population and the target population of the evidence assessors, and being alert for masking mechanisms, which are other mechanisms which may mask the action of the mechanism being assessed.
- Evidence snippets:
  - Snippet 1 (score: 0.639)
    > General mechanistic claim for efficacy. In formulating the general mechanistic claim for efficacy, the following questions should be addressed:
    > • What is the relevant population?
    > • What is the intervention or exposure level?
    > • What is the outcome and how is it measured? General mechanistic claim for external validity. In determining the general mechanistic claim concerning external validity, the following questions should be addressed:
    > • What is the target population? What is the study population?
    > • What is the intervention or exposure level in the target?
    > • What is the outcome and how is it measured in the target?
    > • What is the intervention or exposure level in the study?
    > • What is the outcome and how is it measured in the study?
    > It may be that existing evidence from clinical studies together with already wellestablished mechanisms is enough to establish the general mechanistic claim. In other cases, the existing evidence fails to establish causality, and it is necessary to identify and evaluate mechanistic studies. To this end, this chapter presents the following five-step strategy for gathering evidence of mechanisms:
    > 1. Identify: Identify a number of specific mechanism hypotheses. 2. Formulate: For each specific mechanism hypothesis, formulate a number of review questions. 3. Search: Use these review questions to search the literature. 4. Refine: Identify the evidence most relevant to the mechanism hypothesis by refining the results of this search. 5. Present. Present the evidence relevant to the mechanism hypothesis. This strategy is intended to help overcome some of the practical difficulties with identifying evidence of mechanisms-difficulties which may prevent appraisers from considering all the relevant evidence. Once this evidence of mechanisms has been identified, it can then be evaluated alongside the existing evidence of correlation from clinical studies, as explained in Chaps. 6 and 7.
    > The overall approach of this chapter is illustrated in Fig. 5.1. The five steps outlined above are explained in detail in the following sections.
  - Snippet 2 (score: 0.575)
    > Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations. In this case, it is necessary to determine the status of the following general mechanistic claim: the relevant hypertensive mechanisms in the study populations are sufficiently similar to the mechanisms in African or Caribbean populations. This general mechanistic claim can be evaluated by evaluating a more specific mechanism hypothesis, namely that African and Caribbean populations have a lower renin state. As we shall see in Chap. 6, there is some good mechanistic evidence in favour of this specific mechanism hypothesis, and this undermines the general mechanistic claim. This is why, instead, calcium channel blockers are the recommended antihypertensive treatment in African and Caribbean populations (Clarke et al. 2014).
    > There are two main ways to identify a specific mechanism hypothesis. First, a specific mechanism hypothesis may be proposed on the basis of published studies from the clinical study literature. If a clinical study establishes a correlation between a putative cause and effect, and the suggestion is that this correlation is causal, then the authors of such a study usually identify at least one possible mechanism hypothesis of the following form: It is plausible that mechanism with features F links the putative cause and effect in the study population. The study may also point out possible masking mechanisms (Illari 2011). Given this, the discussion section of a published paper that reports the results of a clinical study is a good place to look in order to locate a specific mechanism hypothesis.
  - Snippet 3 (score: 0.566)
    > The overall approach to gathering evidence of mechanisms of action. Each proposed mechanism of action, or partial description of proposed mechanism of action, is a specific mechanism hypothesis. But note that a specific mechanism hypothesis need not be a complete description of a mechanism.
    > Example: Specific mechanism hypotheses for determining efficacy.
    > Aspirin prevents heart disease via cyclooxygenase (COX) inhibition, and the mechanisms that underlie this prevention are established. However, aspirin also seems to reduce the incidence of some cancers. Here, the mechanisms are much less well understood. As Chan et al. (2011) write: "the mechanism of aspirin's antineoplastic effect is less clear, with substantial evidence supporting both COX-dependent and COX-independent mechanisms. Moreover, data supporting the importance of COX-dependent mechanisms are not entirely consistent concerning the relative importance of the COX-1 and COX-2 isoforms in carcinogenesis". In this quotation, the general mechanistic claim is that aspirin exhibits an antineoplastic effect. There are also a couple of more specific mechanism hypotheses, for example, that this antineoplastic effect is mediated by COX-dependent mechanisms. Evidence relating to these more specific mechanism hypotheses provides a way to determine the status of the general mechanistic claim.
    > External validity. In order to evaluate the general mechanistic claim that there is a mechanism in the target population sufficiently similar to the mechanism responsible for the correlation observed in the study population, specific mechanism hypotheses need to pertain to the mechanism of action. It is important to consider the possibility that the mechanism in the target population may contain further component mechanisms that counteract the mechanism of action in the study population and affect the extent of the correlation between the putative cause and effect. So one needs to ask, are there any masking mechanisms in the target population?
    > Example: Specific mechanism hypotheses for determining external validity.
    > According to NICE guidelines, treatment for hypertension should differ depending on ethnicity (NICE 2011). Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations.

### [2] The fetal origins of adult disease: a narrative review of the epidemiological literature
- Authors: J. Skogen, S. Øverland
- Year: 2012
- Venue: JRSM Short Reports
- URL: https://www.semanticscholar.org/paper/b665dc20a1f7355f7c82e370d1e1fa3a0e2a7fce
- DOI: 10.1258/shorts.2012.012048
- PMID: 23301147
- PMCID: 3434434
- Citations: 102
- Influential citations: 4
- Summary: It is concluded that much of the research literature on the FOAD-hypothesis finds support for the hypothesis, and should be considered a major insight and constitutes a complement to a focus on genetic and more proximal factors (such as adult lifestyle) as causes of adult disease.
- Evidence snippets:
  - Snippet 1 (score: 0.526)
    > The FOAD-hypothesis has been praised as a paradigmatic shift from proximal factors to include distal factors as determinants of disease. 23 Some now argue that the empirical support for the link between an adverse intrauterine environment and later specific disease is so strong, that our focus should be to search for mechanisms. 24 thers criticize the hypothesis on a number of accounts, both methodologically and theoretically.
    > Susser and colleagues 25,26 has argued that the original hypothesis is too vaguely and broadly defined. According to them, stating that a fetus' nutritional status during gestation will influence the disease risk in adulthood, allows researchers to test a near unlimited matrix of potential nutritional measures and any later disease. Such a setting is prone to produce 'Type-I' errors. 27 Secondly, due to the general formulation of the original hypothesis it could not be readily falsified, which is crucial in scientific theory testing. 28 ather, as Paneth and Susser put it: 'example is piled on example, each somewhat consistent with hypothesis but none seriously testing it'. 26 These criticisms have been met to a certain degree by a further refinement of the basic hypothesis, 6 as well as a elaboration of the hypothesis in relation to specific diseases (such as the 'thrifty phenotype'). Additionally, there has been an increased focus on potential mechanisms underlying the proposed causal relationship, 6,11 including research based on animal models and intervention studies involving human subjects. 29 -31 Thus, through a more clear-cut formulation of the hypothesis (and disease-specific sub-hypotheses), development of a theoretical framework, identification of potential mechanisms and replication in animal models, some of the early criticism regarding the FOAD-hypothesis have been addressed. 27 he FOAD-hypothesis has also been criticized on account of how one should interpret the statistical association between anthropometric measures at birth, and outcomes in adulthood. As for any observed association, the relationship could be a result of chance, bias, confounders, or it may be a genuine causal effect. 32 any of the early criticisms of the observed association between anthropometric measures at birth and later disease concerned the lack of adjustment for important third variables. 25

### [3] RareAgent: Self-Evolving Reasoning for Drug Repurposing in Rare Diseases
- Authors: Lang Qin, Z. Gan, Xu Cao, Pengcheng Jiang, Yankai Jiang et al.
- Year: 2025
- Venue: ArXiv
- URL: https://www.semanticscholar.org/paper/ad0dc7cd9de3e46fb22cc025706d54dfe58331a0
- DOI: 10.48550/arXiv.2510.05764
- Summary: RareAgent is presented, a self-evolving multi-agent system that reframes this task from passive pattern recognition to active evidence-seeking reasoning, and improves the indication AUPRC by 18.1% over reasoning baselines and provides a transparent reasoning chain consistent with clinical evidence.
- Evidence snippets:
  - Snippet 1 (score: 0.524)
    > RareAgent operationalizes the scientific discovery process using a team of four AI agents with specialized roles, who collaborate on a shared whiteboard by constructing T-EGraph.
    > • Principal Investigator (PI): The strategic orchestrator. The PI does not directly manipulate evidence but sets research goals, evaluates the state of the T-EGraph, identifies knowledge gaps, issues directives to other agents, and is responsible for self-evolutionary learning loops.
    > • Explorer: The hypothesis generator. The Explorer initiates the investigation by querying the external KG using GNN to propose an initial set of plausible drug-disease hypotheses.
    > • Proponent: The constructive advocate. The Proponent's goal is to build a coherent, mechanistic case for a given hypothesis. It searches for and adds supporting evidence to the T-EGraph, aiming to form complete causal chains (e.g., Drug → Target → Pathway → Phenotype).
    > • Skeptic: The adversarial challenger. The Skeptic's role is to challenge the current hypothesis by finding counter-evidence, identifying risks, and exposing logical fallacies. It adds refuting evidence, such as off-target effects or safety concerns, to the T-EGraph.
    > The overall workflow proceeds in three phases: (1) Hypothesis Generation, where the Explorer seeds the investigation;
    > (2) Iterative Refinement, an autonomous adversarial debate where the Proponent and Skeptic build upon the T-EGraph under the PI's guidance; and (3) Self-Evolution, where the PI analyzes completed investigations to refine agent policies and distill reusable knowledge. All four agents are realized as LLM modules with role-specific policies, and the backbone is swappable and orthogonal to our contributions.

### [4] New Insights into the Pathogenesis of Ovarian Cancer: Oxidative Stress
- Authors: G. Saed, R. T. Morris, N. Fletcher
- Year: 2018
- Venue: Ovarian Cancer - From Pathogenesis to Treatment
- URL: https://www.semanticscholar.org/paper/6c74938095716cbd46a218acde0b4b89bd78f7ae
- DOI: 10.5772/intechopen.73860
- Summary: This chapter provides the reader with up to date most relevant findings on the role of oxidative stress in the pathogenesis and prognosis of ovarian cancer, as well as a novel mechanism of apoptosis/survival in EOC cells.
- Evidence snippets:
  - Snippet 1 (score: 0.508)
    > [11][12][13]. The persistent generation of cellular reactive oxygen species (ROS) is a consequence of many factors including exposure to carcinogens, infection, inflammation, environmental toxicants, nutrients, and mitochondrial respiration [14][15][16][17].
    > The origin and causes of ovarian tumors remains under debate. Injury to surface epithelial ovarian cells due to repeated ovulation is thought to induce tumorigenesis in these cells and is known as the "incessant ovulation hypothesis." Additionally, hormonal stimulation of the surface epithelium of the ovary has been described to initiate tumorigenesis in surface epithelial cells and is known as the "gonadotropin hypothesis." Moreover, the fallopian tube, and not the ovary, has been suggested to be the origin for most epithelial ovarian cancer [2,18,19]. Nevertheless, many cases of ovarian cancer continue to be described as de novo.
    > Histopathologic, clinical and molecular genetic profiles were successfully utilized to clearly discriminate between type I and type II ovarian tumors [19]. Accordingly, type I ovarian tumors develop from benign precursor lesions that implant on the ovary and include clear cell, endometrioid, low-grade serous carcinomas, mucinous carcinomas and malignant Brenner tumors [19]. Type II ovarian tumors develop from intraepithelial carcinomas of the fallopian tube and can then spread to involve both the ovary as well as other sites, such as high-grade serous carcinomas which comprise morphologic and molecular subtypes [19]. Additionally, high-grade endometrioid, poorly differentiated ovarian cancers, and carcinosarcomas are also classified as type II tumors.
    > Attempts to identify specific genes in ovarian tumors to help in early detection of the disease and serve as targets for improved therapy had failed to identify reproducible prognostic indicators [2,[20][21][22]. Several oncogenic mutations and pathways have been identified in ovarian cancer. Specific inherited mutations in the BRCA1 and BRCA2 genes that produce tumor

### [5] A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection
- Authors: F. Langhauser, A. I. Casas, V. Dao, E. Guney, Jörg Menche et al.
- Year: 2018
- Venue: NPJ Systems Biology and Applications
- URL: https://www.semanticscholar.org/paper/44d6cd1d0dd2993b9a9f6b17e3f9705fb04892b8
- DOI: 10.1038/s41540-017-0039-7
- PMID: 29423274
- PMCID: 5799370
- Citations: 61
- Influential citations: 2
- Summary: It is shown that, based on this principle, a cardio-pulmonary drug can be surprisingly repurposed for a previously not recognised application as a direct neuroprotectant, and it is found that the cyclic GMP forming soluble guanylate cyclase becomes dysfunctional upon stroke but regains catalytic activity in the presence of specific activator compounds.
- Evidence snippets:
  - Snippet 1 (score: 0.507)
    > Drug discovery and development follows a relatively uniform path from mechanistic hypothesis, preclinical disease models to clinical validation. However, in recent years, a string of major drug developments have failed due to lack of efficacy. 1 One reason for this appears to reside in our current definitions of 'disease', i.e., mostly organ-based or by an apparent phenotype or symptom and not by an underlying mechanisms. However, without a validated pathomechanism no mechanism-based drugs can be developed and, therefore, rather surrogate parameters or risk factors are treated instead. Finding a rational approach towards mechanism-based disease definitions may therefore have a tremendous impact on drug discovery and medicine in general.
    > Using a data-driven approach, disease-disease networks (diseosome) have been constructed in which diseases are linked based on common molecular or regulatory mechanisms, 2 such as shared genetic associations, 2 protein interactions 3,4 or gene-disease interactions. 5 These diseasomes exhibit local clusters of diseases whose molecular relationships are well understood, but also unexpected clusters of surprisingly heterogeneous diseases. 3 Such clustering of disease phenotypes is likely due to underlying hidden common pathomechanisms. Importantly, these common mechanism clusters may provide previously unrecognized molecular definitions of these phenotypes and at the same time targets for mechanism-based drug discovery and repurposing.
    > Here we test the clinical validity of this approach by focusing on one cluster of highly prevalent combinations of vascular, neurological and metabolic disease phenotypes with high unmet medical need. Genetic evidence points to cGMP signaling as being part of its underlying pathomechanism. 5,6 We then inquire in a non-hypothesis-based manner using disease-disease networks based on common genetic origins, common protein interactions between disease genes, shared disease symptoms and disease co-morbidity for possible drug repurposing of cGMP modulators within this cluster.

### [6] PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas
- Authors: C. Tung, S. Mok, Y. Tsang, Z. Zu, Huijuan Song et al.
- Year: 2009
- Venue: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
- URL: https://www.semanticscholar.org/paper/120fdba92f33c126e0e86008300cb927c4350a14
- DOI: 10.1038/modpathol.2009.92
- PMID: 19525924
- PMCID: 2736318
- Citations: 99
- Influential citations: 8
- Summary: The presence of PAX2 expression in normal ovarian epithelia but expression in fallopian tube fimbria and ciliated epithelial inclusions would suggest the potential development of tumors of low malignant potential and of low-grade ovarian serous carcinomas from secondary Müllerian structures.
- Evidence snippets:
  - Snippet 1 (score: 0.502)
    > Ovarian cancer, a leading cause of cancer deaths among women in the United States, is estimated to affect over 20,000 women each year, with over 15,000 dying of the disease.(1) Serous carcinoma, the major histologic subtype of ovarian cancer, represents about 87% of advanced-staged cases. (2) Currently, no uniform grading system exists despite the fact that histologic grade is a significant prognostic factor in women with epithelial ovarian carcinoma.(3) Malpica et al. proposed a 2-tiered grading system for ovarian serous carcinoma based on nuclear atypia and mitotic rate and classified tumors into low-grade versus high-grade.(4) Low-grade carcinomas and ovarian serous tumors of low malignant potential are often associated together in histologic and molecular studies and are rarely linked with high-grade ovarian carcinoma. (4,5) Differences in clinical behavior further support the distinction between the two grades. Low-grade carcinomas are typically characterized by a younger patient population with longer overall survival and increased platinum chemoresistance compared to high-grade carcinomas. (6) These variations in histologic and clinical behavior have led investigators to suggest that low-grade and highgrade ovarian serous carcinomas may develop along different pathways, and tumors of lowmalignant potential may exist on a continuum with low-grade ovarian serous carcinoma.
    > The precise etiology and pathogenesis of ovarian carcinoma remains elusive despite significant research. The cell of origin is still widely unknown and debated. The most common hypothesis is that ovarian carcinomas develop from the surface epithelium or postovulatory inclusion cysts in response to trauma or prolonged exposure to hormones or other chemokines. (7)(8)(9) However, growing evidence suggests other possible etiologies, including the tubal epithelium and distal endosalpinx. (10,11) Molecular and translational studies have suggested that differences in development pathways may contribute to the clinical, histologic, and genetic differences between low-grade and high-grade ovarian serous carcinomas

### [7] An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment
- Authors: T. Motohara, K. Masuda, M. Morotti, Yiyan Zheng, Salma El-Sahhar et al.
- Year: 2018
- Venue: Oncogene
- URL: https://www.semanticscholar.org/paper/94e8742c8e77f59c6a2648bfdf0d8a9c9c928d7b
- DOI: 10.1038/s41388-018-0637-x
- PMID: 30568223
- PMCID: 6755962
- Citations: 192
- Influential citations: 4
- Summary: The biological mechanisms that regulate the highly orchestrated crosstalk between ovarian cancer cells and various cancer-associated stromal cells in the metastatic tumor microenvironment with regard to the omentum are reviewed to provide further insights into the development of novel therapeutic approaches for patients with advanced ovarian cancer.
- Evidence snippets:
  - Snippet 1 (score: 0.494)
    > cell carcinoma, and mucinous carcinoma [10]. These cancer types are inherently diverse diseases that are characterized by differences in precursor lesions, molecular mechanisms of carcinogenesis, patterns of progression and metastasis, responses to chemotherapy, and clinical outcomes [11][12][13][14]. In the early twenty-first century, a series of morphological and molecular genetic studies led researchers to propose a dualistic model of ovarian carcinogenesis that divided ovarian cancer into two groups: type I and type II [15,16]. High-grade serous carcinoma, which is a prototypical type II tumor, is the most common and extremely aggressive subtype and contributes primarily to the poor prognosis of ovarian cancer patients [5,17,18]. Because of the high metastatic potential of high-grade serous carcinoma, a large proportion of patients are diagnosed at an advanced stage with multiple intraperitoneal disseminated tumors. Furthermore, a marked predilection for the adipose-rich omentum as the site of metastasis can be observed [4,5]. Considering that most ovarian cancer-related deaths are directly attributable to the development of metastatic disease, an in-depth understanding of the cellular and molecular aspects of ovarian cancer metastasis is crucial to overcome this life-threatening disease [19][20][21].
    > Over a century ago, the English surgeon Stephen Paget proposed the "seed and soil" hypothesis, which stated that the pattern of metastasis is not random and that the development of cancer metastasis depends on the crosstalk between particular cancer cells "the seeds" and a specific organ microenvironment "the soil" [22,23]. Since then, extensive efforts have been made to evaluate the reciprocal interactions between cancer cells and tumor microenvironments, which are heterogeneously composed of different cell types, including fibroblasts, endothelial cells, adipocytes, various bone marrow-derived cells, such as myeloidderived suppressor cells, mesenchymal stem cells (MSCs), and macrophages [24,25]. Researchers have shown that a host of strom

### [8] Ranking of cell clusters in a single-cell RNA-sequencing analysis framework using prior knowledge
- Authors: A. Oulas, Kyriaki Savva, Nestoras Karathanasis, George M. Spyrou
- Year: 2023
- Venue: PLOS Computational Biology
- URL: https://www.semanticscholar.org/paper/efaf940a9b0405a5405ebf033673f32b3a1268df
- DOI: 10.1371/journal.pcbi.1011550
- PMID: 38635836
- PMCID: 11060557
- Citations: 1
- Summary: This work presents a novel methodology that exploits prior knowledge for a disease in combination with expert-user information to accentuate cell types from a scRNA-seq analysis that are most closely related to the molecular mechanism of a disease of interest.
- Evidence snippets:
  - Snippet 1 (score: 0.494)
    > The basic analysis flow of our methodology (see Figure 1 -Step 1) begins by performing scRNA-Seq analysis using SEURAT (ver. 4.3.0) (7) The checklist is comprised of pathways and drugs, as well as drug MOAs (optional), associated with the disease. 2) Hypothesis-driven mode: where the user can provide specific keywords/terms associated with the hypothesis under investigation (i.e., to check for signs of inflammation in the different cell types, the user may provide targeted terms associated with inflammation, e.g., Cytokines). For the hypothesis-driven approach, the new keyword terms that are defined are used to perform de-novo querying across the different supported databases (see below). The search extracts the relevant database entries (if any) associated with the keywords. As it may be difficult for the user to provide specific drug names as keywords for this approach, our methodology supports the input of drug MOAs, which can be supplied instead. Our method then proceeds to search and extract the relevant drugs associated with these MOAs using information from the Drug Repurposing Hub Database (https://clue.io/repurposing). The Drug repurposing hub is a curated and annotated collection of FDA-approved drugs, clinical trial drugs, and pre-clinical tool compounds ( 9). This information is made available for our methodology as a text file.
    > The order of the prior knowledge information is important for downstream analytics.
    > For the Discovery mode approach the order is defined by an enrichment score provided by MalaCards. For the Hypothesis-driven approach the user has to define the order of the keywords with most relevant/important keywords provided first.

### [9] DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research
- Authors: Zifeng Wang, Zheng Chen, Ziwei Yang, Xuan Wang, Qiao Jin et al.
- Year: 2025
- Venue: ArXiv
- URL: https://www.semanticscholar.org/paper/f06a59cb27b36766098ecb235c9ada048e145ed0
- DOI: 10.48550/arXiv.2601.11560
- Citations: 2
- Summary: DeepEvidence is introduced, an AI-agent framework designed to perform Deep Research across various heterogeneous biomedical KGs, and demonstrates substantial gains in systematic exploration and evidence synthesis.
- Evidence snippets:
  - Snippet 1 (score: 0.492)
    > Edges represent a controlled set of mechanistic membership association and evidence level relations, and every node and relation is grounded with explicit provenance from primary literature or curated knowledge graphs. Rather than encoding context as free text, the agent attaches short factual observations to entities, capturing experimental setting methodology and quantitative or mechanistic outcomes. During reasoning, the agent queries the existing graph before adding new content, merges near duplicates, updates observations instead of creating redundant nodes, and records conflicting findings with separate evidence links. We add the prompt in Supplementary Note A.4 to the agent's system prompt as additional guidance. This tight coupling between the agent and the evidence graph enables iterative hypothesis refinement, evidence aggregation, and transparent traceability, ensuring that conclusions are derived from an explicit, structured, and auditable body of biomedical evidence.
    > To facilitate cross-knowledge-base research and entity bridging, we implemented unified modality-wise search tools that aggregate information from multiple authoritative sources through a single interface. For instance, the unified gene search tool queries BioThings (MyGene.info), KEGG, and Open Targets simultaneously, returning consolidated results with cross-database identifiers. Similar unified tools exist for diseases, drugs, compounds, targets, pathways, and variants. Beyond entity lookup, we integrated relation-based search capabilities via the PubTator3 API, enabling agents to discover entities linked through specific semantic relationships such as TREAT, CAUSE, INTERACT, INHIBIT, and ASSOCIATE. This allows agents to traverse from diseases to candidate drugs, from genes to associated phenotypes, or from chemicals to their biological targets, supporting the depth-first reasoning patterns essential for mechanistic hypothesis generation. Together, these unified search and relation tools provide the knowledge infrastructure that enables research agents to bridge heterogeneous knowledge graphs and synthesize evidence across multiple biomedical domains.

### [10] Endocrine disruption: fact or urban legend?
- Authors: G. Nohynek, C. Borgert, D. Dietrich, K. Rozman
- Year: 2013
- Venue: Toxicology letters
- URL: https://www.semanticscholar.org/paper/a84380ac3115ab9bed7424722a2049419d87afa3
- DOI: 10.1016/j.toxlet.2013.10.022
- PMID: 24177261
- Citations: 162
- Influential citations: 4
- Summary: Overall, despite of 20 years of research a human health risk from exposure to low concentrations of exogenous chemical substances with weak hormone-like activities remains an unproven and unlikely hypothesis.
- Evidence snippets:
  - Snippet 1 (score: 0.488)
    > tested rigorously and cannot be refuted, it must be tentatively accepted that the hypothesis may be right (Taubes, 2012). On the other hand, if repeated testing fails to generate unequivocal support, the hypothesis should be viewed with scepticism. Let us put the man-made environmental disruptor hypothesis to the test: the hypothesis has now been evaluated experimentally and epidemiologically for nearly 20 years and no convincing evidence has been found of an actual decline in human fertility, and even less of a causal relation with synthetic hormonally active substances.
    > This raises another important issue: epidemiology attempts to determine the cause(s) of an established disease (Susser, 1991). Bacteria, viruses or exposure to toxic substances may cause human diseases. To illustrate this, in the 1950s, a causal relation was established for lung cancer and tobacco smoking. Indeed, lung cancer is a genuine disease with measurable frequency. Its incidence dramatically increased in the 50s, whereas cigarette smoking became increasingly popular in the preceding decades. Exposure was certain, given that tobacco smoke is directly inhaled into the lungs. Thus the hypothesis for a causal relation made biological sense and causality was confirmed by a number of subsequent investigations that involved millions of subjects unequivocally exposed to direct inhalation of tobacco smoke. But how can one determine a cause of a disease when the existence of the disease itself is uncertain? For example, the Testicular dysgenesis syndrome (TDS) is merely a hypothetical disease, in other words: nobody knows whether this disease exists or not -some experts in the field doubt whether TDS exists at all (Thorup et al., 2010). Scientifically and philosophically, the search for a hypothetical cause of a hypothetical disease makes no sense -would it not make more sense to first make sure that the disease actually exists, before spending millions on the quest of its cause? With good reason, the quest for environmental, manmade ED has rightly been titled by the European Molecular Biology Organisation as A Cause without a Disease (Breithaupt, 2004). Nevertheless, we are now witnessing the advent of a massive regulatory programme in search of a justifiable public health purpose (Gori, 2007). Finally, even when a substance is active in an in vitro or in vivo ED assay,

### [11] Learning from our GWAS mistakes: from experimental design to scientific method
- Authors: Christophe Gerard Lambert, L. Black
- Year: 2012
- Venue: Biostatistics (Oxford, England)
- URL: https://www.semanticscholar.org/paper/7c92a4bffd527e9275e5dbc57e2037bc07fa93f9
- DOI: 10.1093/biostatistics/kxr055
- PMID: 22285994
- PMCID: 3297828
- Citations: 60
- Influential citations: 1
- Summary: In an era of large-scale biological research, questions are asked about the role of statistical analyses in advancing coherent theories of diseases and their mechanisms and for renewed appreciation of falsifiable hypotheses so that the authors can learn more from their best mistakes.
- Evidence snippets:
  - Snippet 1 (score: 0.488)
    > Collecting samples without specifying preliminary hypotheses leads to a frame of mind in which genetic assays are run without an experimental design that accounts explicitly for the hypotheses to be tested-in other words, not taking steps to randomize and so prevent biases in data. As with many large biological data collection efforts, GWAS are premised on an overarching hypothesis that a disease has a genetic cause, rather than many more granular hypotheses designed to challenge a causal theory of how a disease manifests. A GWAS might test a million null hypotheses that case-control status and a given genomic SNP are statistically independent over the population sample. The experiment to falsify these null hypotheses is an automated search for indications of association between genetic variants and disease status.
    > In the traditional scientific method, a hypothesis is a proposed explanation for a phenomenon, but scientists use the hypothesis to deduce additional predicted effects which, if observed, can corroborate the hypothesis but not prove it and, if not observed as predicted, can falsify the hypothesis. A single observation can falsify a traditional scientific hypothesis.
    > Such a hypothesis might describe a force or property common to all members of a population. A hypothesis of this sort must make universal claims in order to produce repeatable experiments; then a hypothesis tested by experimenting on a member of the population could be refuted for the entire population. If we abstract a hypothesis-forming process this way-"I have observed property X in a number of instances of A; I hypothesize that all other instances of A will have property X"-then the underlying premise is "All A's are effectively identical." If all A's are effectively identical, then we should accept that a corroborated or refuted hypothesis can inform us about the universe of A's. If A's are billiard balls, and we are looking at properties of how they transfer momentum on a billiard table, we would expect all instances of these A's to have the same properties.

### [12] DiseaseConnect: a comprehensive web server for mechanism-based disease–disease connections
- Authors: Chun-Chi Liu, Y. Tseng, Wenyuan Li, Chia-Yu Wu, I. Mayzus et al.
- Year: 2014
- Venue: Nucleic Acids Research
- URL: https://www.semanticscholar.org/paper/164eec8e3e9af7dd3b1182e46be7577b90d44e1b
- DOI: 10.1093/nar/gku412
- PMID: 24895436
- PMCID: 4086092
- Citations: 100
- Influential citations: 6
- Summary: The DiseaseConnect is a web server for analysis and visualization of a comprehensive knowledge on mechanism-based disease connectivity that integrates comprehensive omics and literature data, including a large amount of gene expression data, Genome-Wide Association Studies catalog, and text-mined knowledge, to discover disease–disease connectivity via common molecular mechanisms.
- Evidence snippets:
  - Snippet 1 (score: 0.481)
    > After viewing all diseases and molecules related to a query disease, users can further explore the shared molecular mechanism(s) between two specific diseases by clicking an edge in the disease network. For example, when a user queries MM, the web server generates a disease-disease network. The user can then click the connection between MM and hemorrhagic disorders (HD) to view a network of shared genes and drugs between HD and MM. Figure 6A shows a small part of this network with the shared gene PSMB5 and the drug bortezomib. PSMB5 is a DEG for both HD and MM, and also has a GeneRIF association with MM. Bortezomib is a therapeutic proteasome inhibitor for treating MM, and targets PSMB5 (39). Interestingly, bortezomib can also treat HD (40), suggesting that shared disease genes can serve as good targets for drug repositioning strategies. Figure 6B shows another example network for the queried disease pair 'arthritis' and 'Crohn disease', both involve the tumor necrosis factor (TNF), based on the data sources GWAS and GeneRIF. Thalidomide is an immunomodulatory drug that targets TNF. Interestingly, thalidomide can treat both arthritis and Crohn diseases (41), supporting our hypothesis that diseases with a shared molecular mechanism are likely to be treated by the same drug. Another drug shown in Figure 6B, 'adalimumab', is known to target TNF and can treat arthritis, suggesting that it may also be effective for Crohn disease. In fact, this inference is confirmed independently by a recent report of Peters et al. (42). Also, several clinical trials about Adalimumab and Crohn disease (e.g. ClinicalTrials.gov ID: NCT01556672 and NCT01958827) are currently ongoing.

### [13] Mechanistic reasoning and the problem of masking
- Authors: Michael Wilde
- Year: 2021
- Venue: Synthese
- URL: https://www.semanticscholar.org/paper/2ca9800e6991ee25dc9a167da8d1f88c3b4f3d94
- DOI: 10.1007/s11229-021-03062-2
- Citations: 4
- Summary: It is argued that it has proved difficult to provide a satisfying answer to when exactly is it appropriate to believe a causal hypothesis on the basis of mechanistic reasoning, and this difficulty is predicted by recent work in knowledge-first epistemology.
- Evidence snippets:
  - Snippet 1 (score: 0.481)
    > thereby appropriately believing the causal hypothesis, thanks to the possibility of non-obvious masking mechanisms.
    > Of course, Howick himself introduced this hormone replacement therapy case as an example of failed mechanistic reasoning (Howick 2011a: pp. 928-930). He therefore acknowledges that the mechanistic reasoning in this example was not enough to appropriately believe the hypothesis that hormone replacement therapy lowered the risk of coronary heart disease. Given this, Howick will likely maintain that in this case the mechanistic reasoning simply did not meet the conditions on high-quality mechanistic reasoning. How exactly did the reasoning fail to meet those conditions? One suggestion would be to maintain that in this case there still remained some obvious gaps in the relevant mechanistic knowledge. But it would then become difficult to explain why it was surprising to learn that it was false that hormone replacement therapy lowered the risk of coronary heart disease. A better suggestion therefore would be to amend the proposed conditions on high-quality mechanistic reasoning so that they require not only that there are no obvious possible masking mechanisms, but also that there are no non-obvious possible masking mechanisms.
    > In effect, the suggestion here is to maintain that it is appropriate to believe a causal hypothesis on the basis of mechanistic reasoning if and only if that reasoning counts as super-high-quality mechanistic reasoning, where super-high-quality mechanistic reasoning meets the following conditions:
    > (1) The knowledge of mechanisms upon which the mechanistic reasoning is based is not incomplete, i.e., there are neither obvious nor non-obvious gaps in our knowledge of the inferential chain linking the intervention and the patient-relevant outcome.
    > (2) The probabilistic and complex nature of the mechanisms are explicitly taken into account when inferring from mechanisms to any claims that a particular intervention has a patient-relevant benefit (cf. Howick 2011b: p. 144)
    > However, the problem now is that it is difficult to carry out such super high-quality mechanistic reasoning, since it is difficult to avoid such non-obvious gaps in our knowledge of the relevant mechanisms. Here is Miriam Solomon:
    > A general problem with mechanistic accounts is that they are typically incomplete, although they often give an illusion of a complete, often linear, narra-tive. Incomplete

### [14] A Resident’s Perspective of Ovarian Cancer
- Authors: Christopher G. Smith
- Year: 2017
- Venue: Diagnostics
- URL: https://www.semanticscholar.org/paper/e7187ce9b848d3233d797ed025fd8984fdc4cd36
- DOI: 10.3390/diagnostics7020024
- PMID: 28448435
- PMCID: 5489944
- Citations: 15
- Influential citations: 3
- Summary: It is demonstrated that regular TVUS examinations can detect ovarian cancer at early stages, and that survival is increased in those women whose ovarian cancer was detected with screening and who undergo standard treatment.
- Evidence snippets:
  - Snippet 1 (score: 0.479)
    > Historically, these cells can either be those that line the surface of the ovary (epithelial) or those that originate from the ovary as non-epithelial cancers (embryonic or extra-embryonic (germ), hormone-producing, or structural cells [sex-cord stromal]) [4][5][6][7][8].In recent years, numerous reports have proposed a unified hypothesis about the origin of high-grade serous ovarian cancer, implicating the Fallopian tubes fimbria as the point of origin [9][10][11][12][13][14][15][16][17][18].In this hypothesis, invasive or serous tubal intraepithelial carcinoma (STIC) originating in the Fallopian fimbria is responsible for seeding the ovaries and peritoneal cavity with malignant cells [19].However, STIC is not present in many high-grade serous carcinomas [20].
    > Ovarian cancer generally affects older women, the average age being 63 [21].Ovarian cancer is the eleventh most common cause of cancer among women, with a lifetime risk of one in 70 to develop disease [22].It is also the leading cause of death from gynecological malignancy.Nearly two thirds of ovarian carcinomas are diagnosed with disease located outside of the pelvis and thereby impose the consequences of advanced stage disease.Overall, the five-year survival rate for women diagnosed with ovarian cancer is 46%.When ovarian cancer spreads to distant sites, five-year survival decreases to 28%, and decreases to nearly 16% with Stage 4 disease [1].

### [15] Robin: A multi-agent system for automating scientific discovery
- Authors: Ali E. Ghareeb, Benjamin Chang, L. Mitchener, Angela Yiu, Caralyn J. Szostkiewicz et al.
- Year: 2025
- Venue: ArXiv
- URL: https://www.semanticscholar.org/paper/799017d2818108e91392c541579cbe9d2cc38e35
- DOI: 10.48550/arXiv.2505.13400
- Citations: 74
- Influential citations: 1
- Summary: Robin is the first AI system to autonomously discover and validate a novel therapeutic candidate within an iterative lab-in-the-loop framework, establishing a new paradigm for AI-driven scientific discovery.
- Evidence snippets:
  - Snippet 1 (score: 0.478)
    > When provided with a disease name, Robin formulates a series of general questions about the disease pathology and queries Crow to answer each question (Supplementary section 5.2). Using the reports from Crow as context, Robin next identifies 10 potential causal disease mechanisms. For each mechanism, Robin again deploys Crow to prepare a detailed report describing an in vitro model of the disease mechanism and corresponding assay that can be used to test drug efficacy. Robin uses an LLM judge to make pairwise comparisons between reports, which are used to calculate their relative rankings (see Methods). The top-ranked in vitro model is used by Robin to define the experimental strategy for therapeutic candidate hypothesis generation. Once an in vitro model is selected, Robin conducts a similar sequence of general literature review and hypothesis generation to propose 30 therapeutic candidates for experimental testing. Robin then queries Falcon to generate a detailed report to evaluate each candidate. These reports contain both justification for why each drug is suitable for mitigating the disease mechanism represented in the in vitro model and potential limitations the drug may pose. The drug candidates are ranked by an LLM-judged tournament according to the strength of the scientific rationale, pharmacological profile, and methodology of the supporting literature. This ranked list can then be reviewed by human scientists, and top drug candidates can be tested in the lab by executing an experimental protocol based on the assay suggested by Robin.

### [16] SKiM-GPT: combining biomedical literature-based discovery with large language model hypothesis evaluation
- Authors: Jack Freeman, R. Millikin, Leo Xu, Ishaan Sharma, Bethany Moore et al.
- Year: 2025
- Venue: BMC Bioinformatics
- URL: https://www.semanticscholar.org/paper/ce7a6900a181708dba6ed2bf612d06b0be1d20b1
- DOI: 10.1186/s12859-025-06350-7
- PMID: 41408154
- PMCID: 12829140
- Summary: SKiM-GPT is introduced, a retrieval-augmented generation (RAG) system that combines SKiM’s co-occurrence search and retrieval with frontier LLMs to evaluate user- defined hypotheses, and achieves strong ordinal agreement with four expert biologists, demonstrating its ability to replicate expert judgment.
- Evidence snippets:
  - Snippet 1 (score: 0.476)
    > B Positive hypothesis condition. Without any provided abstracts ("No text"), when asked whether each drug "improves breast-cancer patient outcomes, " SKiM-GPT assigns positive scores (median = + 2), indicating that parametric (trained) memory is biased towards positive scores in these cases as expected ("parametric-knowledge leakage"). C Neutral hypothesis condition. Feeding synthetic abstracts that state no relationship exists between the drug and breast cancer patient outcomes increases scores for neutral hypotheses (median = + 2) for all drugs, indicating the model grounds its judgment in the supplied context rather than internal bias. D Negative hypothesis condition. Providing synthetic abstracts that refute drug efficacy results in increased scores for negative hypotheses (median = + 2). Together, panels B-D indicate that SKiM-GPT's scores mirror the sentiment of the abstracts rather than the LLM's training data SKiM-GPT correctly classified 19 of them, confirming 16 true drug-gene treatment links (positive scores) and correctly discarding three false positives (zero or negative scores). In the one case where SKiM-GPT was unable to correctly classify, the gene name SLN returned no relevant abstracts, as the abbreviation SLN can also stand for "sentinel lymph node" which is often a term associated with cancers.
    > Table 2. Assessment of SKiM-GPT's ability to remove false-positive hits in an LBD search. "Breast Cancer" was used as the A-term, a list of human genes as B-terms, and FDA-approved drugs as C-terms. The hypothesis "{C-term} treats {A-term} through its effect on {B-term}" was used to evaluate the top 20 hits ranked by p-value. For each SKiM A-B-C hit (column 1), SKiM-GPT scores the provided hypothesis from −2 (strongly refutes) to + 2 (strongly supports) after relevance filtering (column 2). Scores were classified as a true-positives (TP) or true-negatives (TN) based on current clinical or mechanistic evidence (column 3). The comments (column 4) contain context-specific notes written by human judges.

### [17] MicroRNAs as Key Regulators of Ovarian Cancers
- Authors: S. Satapathy, Chanchal Kumar, R. Singh
- Year: 2019
- Venue: Cell Medicine
- URL: https://www.semanticscholar.org/paper/15e1b4b2236e99d2745e80baf8a98f3b45e8f432
- DOI: 10.1177/2155179019873849
- PMID: 32634196
- PMCID: 6732848
- Citations: 2
- Summary: This review focuses on microRNAs that are dysregulated in ovarian carcinomas, their effect on the components of the tumor microenvironment, and the correlation of their heterogeneous expression profiles with disease severity and prognosis in patients.
- Evidence snippets:
  - Snippet 1 (score: 0.472)
    > Ovarian cancers are among the global leading cause of malignancy-associated death in women 1 . Each year approximately 240,000 women are diagnosed with ovarian cancer across the globe, reflecting the high prevalence and associated fatality of the disease 2 . The most common subtypes of these ovarian carcinomas include epithelial ovarian carcinomas (80-90%), with few cases of germ cell cancers (1-2%) 3 . Among the epithelial ovarian carcinomas, serous ovarian cancers (SOCs) or high-grade serous ovarian cancers (HGSOCs) result in most of the gynecological malignancies 4 . Research on ovarian cancer over the past few years has associated geographical variations and populationspecific susceptibility factors with disease progression, and therefore needs further research and analysis 4 .
    > The most commonly adopted clinical intervention for ovarian cancers involves "mass debulking," sometimes combined with chemotherapy and radiotherapy 3 . Recently the use of hormone and antibody-based treatment methodologies in patients with ovarian cancer has gained momentum 5 . However, these approaches of treatment still depend on the patients' health constitution and prior medical history, and have been often associated with side-effects such as fatigue, nausea, hair loss, neuropathies, and inflammatory bowel disease, etc 5 . A major constraint in understanding the disease biology is the association of ovarian carcinomas with low survival rate post diagnosis, low to poor prognosis of the disease, and rapid tumor relapse (based on the repopulation hypothesis). Often cases of aggressive ovarian cancers are diagnosed among women in the age group of 50-70 years, with approximately 80% of these cases being diagnosed at the late stage of cancer 4 . In addition, patients with ovarian cancers are reported to have low mean 5-year survival rates; these typically range between 20% and 40%, especially for those with HGSOCs 5 .

### [18] A General Framework for Formal Tests of Interaction after Exhaustive Search Methods with Applications to MDR and MDR-PDT
- Authors: T. Edwards, Stephen D. Turner, E. Torstenson, S. Dudek, E. Martin et al.
- Year: 2010
- Venue: PLoS ONE
- URL: https://www.semanticscholar.org/paper/4de432bf6a4637abd951bbda473ccc57ca98128c
- DOI: 10.1371/journal.pone.0009363
- PMID: 20186329
- PMCID: 2826406
- Citations: 15
- Influential citations: 1
- Summary: A valid regression-based permutation test procedure is provided that performs a valid test of interaction after a search for multilocus models, and can be applied to any method that conducts a search to find aMultilocus model representing an interaction.
- Evidence snippets:
  - Snippet 1 (score: 0.470)
    > This means that while MDR is sensitive to detect multi-locus association signals; these associations can be due to true interactions associating with the trait or multiple main effects without interaction. Both situations will lead to rejection of the null hypothesis of no association between genotypes and disease from the permutation test. Since association of multi-locus genotypes with the trait is the formal alternative hypothesis of the MDR and MDR-PDT hypothesis tests, this is not technically a type I error; however, if one is primarily interested in detecting true interactions and not simply finding combinations of associated loci, a rejection of the null ought to reliably represent support for the alternative hypothesis of interaction. With the original structure of the hypothesis test, this issue remained ambiguous after hypothesis testing, and obtaining an unbiased evaluation of MDR or MDR-PDT model properties with regard to synergy required an independent sample.
    > In contrast, parametric statistics such as logistic regression [14] have limited utility when searching for interactive effects in a large search space, whether searching through genetic loci [15] or environmental exposures [16]. These methods do not natively adjust for many comparisons or accommodate scenarios with high dimensionality. As the number of predictor variables increases, the number of comparisons necessary to explore the entire epistatic search space expands rapidly, decreasing the power to reject the null after an inefficient correction for multiple tests. However, these methods do provide some important advantages over the nonparametric alternatives, such as estimation of population parameters, adjustment for covariates, and ease of use and interpretability. A further advantage of the regression framework is the specificity of the hypothesis tests, particularly for testing interaction. While MDR and MDR-PDT test one composite null hypothesis, H 0A : no association (main effects) and H 0I : no interaction, regression is able to evaluate the null hypothesis in two parts, allowing a test for H 0I versus H 1I . This property of regression-based hypothesis testing is necessary for an algorithm to find reliable evidence for epistasis in genetic studies.

## Notes

- This provider combines `search_papers_by_relevance` with `snippet_search`.
- No synthesis or second-stage model call is performed.
